Drug Pricing: Page 11
-
Getty / Edited by BioPharma Dive
Value-based pricing for gene therapy? Maybe not ready for hemophilia
A small patient population plus large potential savings could make blood-clotting gene therapies an easier sell to payers, biotech executives say.
By Jonathan Gardner • Dec. 11, 2019 -
Deep Dive
Will sky-high drug prices spur the US to use an obscure power over patents?
New cell therapies as well as gene-based treatments like Zolgensma benefited from NIH funding of early-stage research. Advocates say the time is now for the government to invoke its "march-in" rights.
By Jonathan Gardner • Dec. 4, 2019 -
Global Blood's sickle cell drug wins FDA approval, joining Novartis' Adakveo
A list price of roughly $10,000 a month puts Global Blood's Oxbryta slightly higher than what Novartis' Adakveo will cost.
By Jonathan Gardner • Updated Nov. 26, 2019 -
France clears way for wide use of Vertex's Orkambi
By agreeing to reimburse the drug beyond compassionate use, France opens up access to one of the largest cystic fibrosis populations outside the U.S.
By Jonathan Gardner • Nov. 20, 2019 -
ICER draws new gene therapy pricing framework
One-time and short-term curative therapies require a different approach to evaluating benefit, the cost watchdog group said.
By Jonathan Gardner • Nov. 13, 2019 -
Trump administration sues Gilead over HIV drug patents
Accused of unfairly profiting from government research, Gilead said it will ask the district court to stay HHS' suit until the U.S. Patent Office reviews the disputed patents.
By Ned Pagliarulo • Updated Nov. 7, 2019 -
Third Neulasta biosimilar on its way as Sandoz wins long-delayed FDA approval
Novartis' drug will be third to market, but copycat drugs have already taken a chunk of the market away from Amgen's branded version.
By Jonathan Gardner • Nov. 5, 2019 -
Allergan pays $750M to rid itself of Namenda antitrust charges
A class action suit followed the New York attorney general in claiming the big pharma tried to delay generic competition to its Alzheimer's drug.
By Jonathan Gardner • Oct. 28, 2019 -
Pelosi drug plan would save $370B, but could reduce R&D, forecasters say
Pharma would respond to Pelosi's proposal by raising list prices, keeping some drugs off foreign markets, and cutting R&D spending, according to the CBO.
By Jonathan Gardner • Oct. 14, 2019 -
Elizabeth Regan/BioPharma Dive
With new report, ICER puts itself at center of drug pricing storm
Pharma price hikes added billions of dollars to U.S. spending in 2017 and 2018. For seven top drugs, the watchdog found those increases came with little new clinical evidence in support.
By Ned Pagliarulo • Updated Oct. 8, 2019 -
Buttigieg targets pharma in aggressive plan to lower drug prices
The presidential hopeful supports several policies, such as direct drug price negotiation, that feature in legislation proposed by House Democrats.
By Ned Pagliarulo • Oct. 7, 2019 -
Top Pelosi aide to payers: Help us defeat Big Pharma
Wendell Primus' pitch sparked debate between policy experts and industry representatives Monday at AHIP's annual conference.
By Samantha Liss • Sept. 24, 2019 -
States pull back curtain on drug prices, to uncertain effect
A newly enacted law in Colorado requires pharma companies inform doctors of list prices, as well as the names of three generics in the same treatment class.
By Ned Pagliarulo • Sept. 23, 2019 -
Novo gains approval for first oral diabetes drug of its kind
The list price for Rybelsus will be competitive within the GLP-1 drug class, Novo said, which may make it more expensive than other glucose-lowering pills.
By Jonathan Gardner • Updated Sept. 24, 2019 -
The top drugs facing cuts under Pelosi's pricing plan
Democrats' plan would put pressure on top-sellers from Bristol-Myers Squibb, Regeneron and Merck & Co, among others.
By Jonathan Gardner • Sept. 20, 2019 -
House Democrats forge ahead with direct Medicare drug price negotiation
While drug price constraints may still become law, House Speaker Nancy Pelosi's proposal looks like a long shot.
By Jonathan Gardner • Sept. 19, 2019 -
Regulatory barriers limit alternative state drug payment models
Forced to balance higher costs with public health goals, more states are looking at alternative payment models for prescription drugs in Medicaid.
By Samantha Liss • Sept. 18, 2019 -
Deep Dive
Public trust in drugmakers is at an all-time low. Can biopharma recover?
Leaders are grappling with how to improve the industry's reputation at a time when the broader business world is under increased scrutiny.
By Andrew Dunn • Sept. 11, 2019 -
ICER dings Novo's new oral diabetes drug
The semaglutide pill is less effective than Jardiance and more expensive if priced similarly to the drug's injectable form, ICER said in a draft report.
By Jonathan Gardner • Sept. 11, 2019 -
Medicare would negotiate prices for 250 drugs under House Democrats' plan
Speaker Nancy Pelosi's proposal also finds common ground with the president in pegging U.S. prices to an international index.
By Jonathan Gardner • Sept. 10, 2019 -
Kendall Davis/BioPharma Dive
Deep DiveUnblinded: Rebekah Gee's drug pricing experiment in Louisiana
Louisiana's health secretary negotiated a new payment model with Gilead for one of the poorest states in the country. Could it spread nationwide?
By Andrew Dunn • Aug. 28, 2019 -
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
Out-of-pocket spending on MS medications increased by more than 600% in the decade from 2006 to 2016, while the typical list price quadrupled.
By Andrew Dunn • Aug. 27, 2019 -
Brian Tucker/BioPharma Dive
Congress is going after drug prices. Pharma CEOs aren't panicking, yet
A Senate Finance bill could emerge as the most palatable option for an industry seeking to limit losses in an election cycle already targeting pricing as an issue.
By Ned Pagliarulo • Aug. 2, 2019 -
Medicines Co. awaits its date with destiny
After slimming down to focus on one big R&D bet, the company needs inclisiran to match or outperform on-market PCSK9 drugs Repatha and Praluent.
By Jonathan Gardner • Aug. 1, 2019 -
Teva, Endo among generics paying $70M in California pay-for-delay settlement
The state accused Teva, Endo and Japan-based Teikoku of anticompetitive practices on two drugs, which it said drove healthcare costs higher.
By Jacob Bell • July 29, 2019
Previous
